Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZOLVE-AD: Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
NCT06136741Phase 2Active, not recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 10
01
Overview
A Phase 2 trial of rezpegaldesleukin in atopic dermatitis (AD), sponsored by Nektar Therapeutics. Started Nov 2023; status: active, not recruiting.
02
Drugs
rezpegaldesleukin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06136741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136741.